Table 1

Cardiovascular outcomes in the EMPA-REG OUTCOME study

CV outcomePlacebo group (n = 2,333)Pooled empagliflozin group (n = 4,687)Relative risk reduction
CV death, nonfatal MI/stroke12.110.5−14*
Death from any cause8.35.7−32*
CV death5.93.7−38*
Hospitalization for HF14.59.4−35*
Fatal/nonfatal MI (excludes silent MI)5.44.8−13**
Nonfatal stroke3.03.5+24**
  • Data are %.

  • *Significant.

  • **Nonsignificant.